Trial Profile

A Phase 2 Clinical Trial of a Gene-Replacement Therapy for the Treatment of Friedreich's Ataxia

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 03 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AVB 202 (Primary) ; AVB 202 (Primary)
Indications Friedreich's ataxia
Focus Therapeutic Use
Sponsors AavantiBio; Solid Biosciences

Most Recent Events

05 Dec 2022 According to a Solid Biosciences media release, AavantiBio has been acquired and merged with Solid Biosciences.
20 Jan 2020 New trial record
13 Jan 2020 According to a Muscular Dystrophy Association media release, the Muscular Dystrophy Association (MDA) and AavantiBio today announced the award of MDA Venture Philanthropy (MVP) funding totaling $1,076,232 to advance this AavantiBios phase 2 clinical trial of a gene-replacement therapy for the disease.This trial is expected to begin in 2020 (before the end of the year).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com